EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

HLA-DQA1*05 and HLA-DQA1*05/HLA-DQB1*02 Co-Carriage in Relation to Anti-TNF Antibody Concentrations and Response in Iraqi Patients with Inflammatory Bowel Disease

Ban AbdulWahid Kanna, Suha Saeed Azeez

International Journal of Molecular Sciences · 19.11.2026 · 27 (22) · 10406

DOI: 10.3390/ijms272210406 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 19.11.2026. Verfasst von Ban AbdulWahid Kanna und 1 weiteren Autor:innen. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

HLA-DQA1*05 has been associated with anti-TNF immunogenicity, but evidence from Iraqi patients remains limited. We explored associations of HLA-DQA1*05 and HLA-DQA1*05/HLA-DQB1*02 co-carriage with anti-drug antibody (ADAb) concentrations, trough concentrations, and response during maintenance treatment. This single-center cross-sectional analysis included 80 adults receiving infliximab (n = 41) or adalimumab (n = 39). Serum anti-TNF trough concentrations and ADAb levels were measured using an enzyme-linked immunosorbent assay. Real-time PCR detection of both targets defined unphased co-carriage. Drug-specific models used log concentrations with HC3 robust inference or logistic regression for response, adjusting for current azathioprine use. There were 55 HLA-DQA1*05 carriers, 20 haplotype co-carriers, and 38 responders. No adjusted primary or secondary genetic comparison met the multiplicity-adjusted significance threshold. Adjusted response odds ratios for HLA-DQA1*05 carriers were 0.29 (95% CI 0.06–1.36, p = 0.115) for infliximab and 1.35 (0.34–5.32, p = 0.670) for adalimumab; haplotype co-carriage estimates were 1.24 (0.26–5.78, p = 0.787) for infliximab and 0.63 (0.15–2.73, p = 0.540) for adalimumab. Exploratory component analysis found CRP < 5 mg/L in 15/29 infliximab DQA1*05 carriers versus 12/12 non-carriers (p = 0.003; q = 0.024). Neither the HLA-DQA1*05 genotype nor the HLA-DQA1*05/HLA-DQB1*02 haplotype provides evidence of significant associations with ADAb concentrations, serum trough levels, or therapeutic response in either infliximab- or adalimumab-treated patients (all p > 0.05). In this Iraqi IBD cohort, interpretation of estimates regarding the association of the HLA-DQA1*05 genotype and the HLA-DQA1*05/HLA-DQB1*02 haplotype should be expressed cautiously, and clinically meaningful associations cannot be excluded.

Zitieren

APA

Kanna, B. A., & Azeez, S. S. (2026). HLA-DQA1*05 and HLA-DQA1*05/HLA-DQB1*02 Co-Carriage in Relation to Anti-TNF Antibody Concentrations and Response in Iraqi Patients with Inflammatory Bowel Disease. International Journal of Molecular Sciences, 27(22), 10406. https://doi.org/10.3390/ijms272210406

Vancouver

Kanna BA, Azeez SS. HLA-DQA1*05 and HLA-DQA1*05/HLA-DQB1*02 Co-Carriage in Relation to Anti-TNF Antibody Concentrations and Response in Iraqi Patients with Inflammatory Bowel Disease. International Journal of Molecular Sciences. 2026;27(22):10406. doi:10.3390/ijms272210406

BibTeX
@article{Kanna2026,
  author = {Kanna, Ban AbdulWahid and Azeez, Suha Saeed},
  title = {HLA-DQA1*05 and HLA-DQA1*05/HLA-DQB1*02 Co-Carriage in Relation to Anti-TNF Antibody Concentrations and Response in Iraqi Patients with Inflammatory Bowel Disease},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  volume = {27},
  number = {22},
  pages = {10406},
  doi = {10.3390/ijms272210406}
}
Kostenlos starten →